TARS · 59.85 (last weekly close)■ SMA 10w■ SMA 40w
Weekly candles over the last 52 weeks, split-adjusted, with 10- and 40-week moving averages; trading volume along the bottom. As of Jul 13, 2026.
OakBag could not build a reliable fair-value estimate for Tarsus Pharmaceuticals, Inc (TARS) — none of its valuation methods cleared the model's safety checks (typically a company running an operating loss, where a discount can't be trusted). At a recent price of $59.85 the traffic light is set so it looks expensive or risky, benchmarked against other Health Care names. This is a model output for research, not a price target or a recommendation.
OakBag could not build a reliable fair-value estimate for Tarsus Pharmaceuticals, Inc — none of its valuation methods cleared the model's safety checks, which usually happens for a company running an operating loss. At a recent price of $59.85 the model looks expensive or risky. This is a model output, not investment advice.
What is margin of safety?
Margin of safety is how far below the estimated fair value the price sits: (fair value − price) ÷ fair value. It cannot be shown here because no reliable fair-value estimate could be built for this stock.
Does a green verdict mean I should buy TARS?
No. OakBag is an educational and research tool, not investment advice. The traffic light is an automated model output based on third-party data that may be delayed or inaccurate. Always do your own research.
An educational and research tool — not investment advice. OakBag is an educational and research tool, not investment advice. Scores and rankings are automated model outputs based on third-party data and may be inaccurate or delayed. Nothing here is a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal.